tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Ecthyma, Contagious D004474 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Dinçkan A et al. Evaluation of the first 100 liver transplantations. 2008 Turk J Gastroenterol pmid:18386237
Bajetta E et al. Merkel cell carcinoma after liver transplantation: a case report. 2007 May-Jun Tumori pmid:17679476
Vennarecci G et al. [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. 2003 Jul-Aug Tumori pmid:12903579
Sommerer C et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. 2016 Trials pmid:26888217
Nashan B et al. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. 2015 Trials pmid:25873064
Snyder SH et al. Neural actions of immunophilin ligands. 1998 Trends Pharmacol. Sci. pmid:9509898
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. 2003 Apr-May TreatmentUpdate pmid:17216847
Jain A et al. Pregnancy after liver transplantation under tacrolimus. 1997 Transplantation pmid:9293865
Garcia-Criado FJ et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. 1997 Transplantation pmid:9293871
Satterthwaite R et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. 1998 Transplantation pmid:9484771
Garrity ER and Mehra MR An update on clinical outcomes in heart and lung transplantation. 2004 Transplantation pmid:15201689
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Boldt A et al. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. 2006 Transplantation pmid:16906043
Gaber AO et al. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. 2013 Transplantation pmid:23423269
Guethoff S et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. 2013 Transplantation pmid:23423270
Miyakoshi S et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. 2007 Transplantation pmid:17700155
Fujita T et al. Prolonged survival of rat skin allograft by treatment with FK506 ointment. 1997 Transplantation pmid:9326422
Jain AB et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. 2004 Transplantation pmid:15077034
Huang E et al. Alemtuzumab induction in deceased donor kidney transplantation. 2007 Transplantation pmid:17984833
Jain A et al. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. 2014 Transplantation pmid:25285953
Eiras G et al. Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506. 1990 Transplantation pmid:1694318
Maes BD et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. 2001 Transplantation pmid:11726827
Kahan BD An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. 1999 Transplantation pmid:10428260
Washburn K et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. 2001 Transplantation pmid:11726831
Jordan ML et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. 1999 Transplantation pmid:10075592
Min DI et al. Circadian variation of tacrolimus disposition in liver allograft recipients. 1996 Transplantation pmid:8900327
Jindal RM et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7519799
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Borrows R et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. 2006 Transplantation pmid:16421488
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Naesens M et al. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. 2008 Transplantation pmid:18431234
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. 1996 Transplantation pmid:8878382
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
Klein IH et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. 2002 Transplantation pmid:11907418
Ringe B et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. 2001 Transplantation pmid:11258429
Cantarovich D et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. 2005 Transplantation pmid:15714172
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Thomas PG et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. 2007 Transplantation pmid:17565326
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
Egashira K et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. 2003 Transplantation pmid:12698101
Kuypers DR et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. 2013 Transplantation pmid:23263559
White M et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. 2006 Transplantation pmid:17006323
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356